HomeAbstract of 2nd-agconfFAERS Analysis Reveals Significant Age-Related Differences in the Adverse Event Profiles of High-Potency Antipsychotics

FAERS Analysis Reveals Significant Age-Related Differences in the Adverse Event Profiles of High-Potency Antipsychotics

  • Mar 12, 2025
  • Posted by: admin
  • Category: Abstract of 2nd-agconf
No Comments

Proceedings of the 2nd Global Conference on Aging and Gerontology

Year: 2025

DOI:

[PDF]

FAERS Analysis Reveals Significant Age-Related Differences in the Adverse Event Profiles of High-Potency Antipsychotics

Jens-Uwe Peter, Tabea Ramin, Michael Schneider, Volker Dahling, Oliver Zolk

 

ABSTRACT:

Older patients are generally more vulnerable to the risks of antipsychotic medications. However, because they are often excluded from clinical trials, comparative data on adverse drug reactions for specific antipsychotics are lacking. This study examines the adverse effect profiles of the most frequently prescribed antipsychotics in patients aged <65 and ≥65 years using pharmacovigilance data, with additional analysis of sex-based differences. We analyzed adverse event (AE) reports associated with aripiprazole, clozapine, olanzapine, quetiapine, risperidone, and haloperidol from the FDA Adverse Event Reporting System (FAERS) database from 2003 to 2024. Eighteen AE categories were examined and logistic regression models were used to calculate adjusted reporting odds ratios (aRORs). Our analysis revealed drug-specific differences in AE profiles. Risperidone had the highest aROR for hyperprolactinemia (aROR 212), haloperidol for dystonia (aROR 46), and aripiprazole for akathisia (aROR 45). In comparisons between age groups, patients aged ≥65 years were generally more likely to experience cardiac, extrapyramidal motor, and sedative AEs but had a lower likelihood of metabolic AEs (dyslipidemia, hyperglycemia, weight gain) compared to those under 65. Regarding sex differences, women had a similar or higher risk of AEs compared to men across all drugs studied, with few exceptions. Notably, the aRORs for anticholinergic syndrome with aripiprazole and olanzapine were three to six times higher in men than in women. Understanding age- and sex-related differences in the AE profiles of individual antipsychotics is crucial for personalized drug selection. This study provides valuable insights that may enhance the tolerability of antipsychotic therapy in older patients.

keywords: pharmacovigilance, side effects, schizophrenia, geriatric psychiatry, reporting odds ratio